PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-4.59%
Both companies show declining cash positions (-4.59% vs GNPX's -61.17%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
-40.54%
Both GNPX and the company show zero Short-Term Investments Growth.
-4.61%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of GNPX's -50.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
10.64%
Higher PP&E (Net) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.58%
Below half of GNPX's -4.04%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half of GNPX's -36.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.14%
Less than half of GNPX's -38.99%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
-34.95%
Less than half of GNPX's 144.34%. David Dodd sees fewer expansions in other current obligations.
-29.36%
Less than half of GNPX's 13.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.36%
Less than half of GNPX's 13.75%. David Dodd sees far fewer liability expansions relative to competitor.
3.53%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
-3.88%
1.25-1.5x GNPX's -2.94%. Bruce Berkowitz notes stronger reinvestment strategy.
-25.46%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
Below half GNPX's -64.03%. Michael Burry sees potential underperformance in building shareholder capital.
-4.86%
Below half GNPX's -36.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-40.54%
Both GNPX and the company show zero Total Investments Growth.
-100.00%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
4.24%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.